Video

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

19 October 2025
Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

18 October 2025
Giredestrant plus everolimus may represent a new effective treatment option in ER+, HER2– advanced breast cancer, post-CDK4/6 in

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

18 October 2025
Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others

18 October 2025
Enhancing breast cancer care through AI and collaboration

Enhancing breast cancer care through AI and collaboration

9 October 2025
NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

8 October 2025
Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients

Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients

8 October 2025
Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

8 October 2025
ctDNA testing improves detection of treatable metastases compared to standard care

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer

8 October 2025
ADT + PORT is an excellent treatment option for men with unfavourable intermediate risk or favourable high risk PC

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

7 October 2025
Back to Top